InChI key
POGQSBRIGCQNEG-UHFFFAOYSA-N
SMILES string
NC(=O)c1cn(Cc2c(F)cccc2F)nn1
InChI
1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
grade
certified reference material
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
concentration
500 μg/mL in methanol
format
single component solution
storage temp.
−20°C
Application
An antiepileptic drug and anticonvulsant, Rufinamide is approved for the treatment of partial seizures associated with Lennox-Gastaut syndrome in adults and children 4 years and older.
Legal Information
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes,Central nervous system
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
新产品
此项目有
Maria G Dahlin et al.
Neuropediatrics, 43(5), 264-270 (2012-09-04)
We examined the influence of age and type of concomitant antiepileptic drugs (AEDs) on the pharmacokinetics of rufinamide (RUF) as well as its efficacy and safety in 51 children with refractory epilepsy. In a retrospective noninterventional survey, dose-to-concentration ratios of
C von Stülpnagel et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 16(5), 459-463 (2012-01-24)
We evaluated the long-term efficacy and tolerability of the orphan drug rufinamide (RUF) in children with pharmacoresistant myoclonic-astatic epilepsy (MAE, Doose syndrome). This was a retrospective European multicenter study on eight patients who had started an intention-to-treat trial of RUF
Isabelle Mourand et al.
Epilepsia, 54(1), e5-e8 (2012-07-12)
Rufinamide (RUF) is a novel antiepileptic drug considered as second-line therapy in the treatment of Lennox-Gastaut syndrome. Treatment-emergent adverse events (AEs) have consisted mainly of drowsiness, irritability, vomiting, and loss of appetite. RUF is considered as a "weight-neutral" drug. We
Martina Vendrame et al.
Epileptic disorders : international epilepsy journal with videotape, 13(1), 18-21 (2011-03-12)
The syndrome of malignant migrating partial seizures of infancy (MMPEI) is characterized by early onset of multiple seizures types, highly pharmaco-resistant seizures, and overall poor prognosis. In this study, we investigated retrospectively the efficacy of rufinamide (RUF) in five infants
Danièle Bentué-Ferrer et al.
Therapie, 67(2), 161-165 (2012-08-02)
Rufinamide is a third-generation antiepileptic drug, available since early 2010 in France. It is indicated in combination therapy in the Lennox-Gastaut syndrome from the age of 4. It has orphan drug status. The bioavailability of rufinamide is high, but decreases
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持